Is Cellectar Biosciences Inc (CLRB) Stock a Good Buy on Friday?

Friday, July 24, 2020 10:01 AM | InvestorsObserver Analysts

Overall market sentiment has been down on Cellectar Biosciences Inc (CLRB) stock lately. CLRB receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bearish
Cellectar Biosciences Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CLRB!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.

InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CLRB Stock Today?

Cellectar Biosciences Inc (CLRB) stock is trading at $1.37 as of 9:58 AM on Friday, Jul 24, a decline of -$0.04, or -2.83% from the previous closing price of $1.41. The stock has traded between $1.36 and $1.42 so far today. Volume today is light. So far 70,207 shares have traded compared to average volume of 859,125 shares.

To see the top 5 stocks in the Biotechnology industry click here.

More About Cellectar Biosciences Inc

Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

European ADRs Move Sharply Higher in Monday Trading

What is the Forecast Price for Puma Biotechnology Inc (PBYI) Stock?

Is The Ensign Group, Inc. (ENSG) Stock Worth a Buy Monday?

Is Novo Nordisk A/S (NVO) Stock a Smart Investment?

Asian ADRs Climb Higher in Monday Trading

Do Traders View Healthequity Inc (HQY) Stock's Current Trend Positively?

Related Companies